Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

• 資料種別: 記事
• タイトル: Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial
• 著者標目: Kensei Yamaguchi; https://orcid.org/0000-0001-6887-5709; Yung-Jue Bang; https://orcid.org/0000-0001-6000-4597; Satoru Iwasa; https://orcid.org/0000-0003-3863-9582; Naotoshi Sugimoto; Min-Hee Ryu; Daisuke Sakai; https://orcid.org/0000-0003-4189-9270; Hyun Cheol Chung; https://orcid.org/0000-0002-0920-9471; Hisato Kawakami; https://orcid.org/0000-0002-3280-4850; Hiroshi Yabusaki; Jeeyun Lee; https://orcid.org/0000-0002-4911-6165; Tatsu Shimoyama; Keun-Wook Lee; https://orcid.org/0000-0002-8491-703X; Kaku Saito; Yoshinori Kawaguchi; Takahiro Kamio; Akihito Kojima; Masahiro Sugihara; Kohei Shitara; https://orcid.org/0000-0001-5196-3630
• 出版年月日等: 2023-02-01
• 出版年（W3CDTF）: 2023-02-01
• タイトル（掲載誌）: Journal of Clinical Oncology
• 巻号年月日等（掲載誌）: 41 4
• 掲載巻: 41
• 掲載号: 4
• 掲載ページ: 816-825
• 掲載年月日（W3CDTF）: 2023-02-01
• ISSN（掲載誌）: 0732183X
• 出版事項（掲載誌）: American Society of Clinical Oncology (ASCO)
• 件名標目: Receptor, ErbB-2; Stomach Neoplasms; Humans; ORIGINAL REPORTS; Esophagogastric Junction; Trastuzumab; Adenocarcinoma; Antibodies, Monoclonal, Humanized
• 対象利用者: 一般
• 標準番号（その他）: PMID : 36379002
• DOI: 10.1200/jco.22.00575
• 作成日（W3CDTF）: 2022-11-15
• オンライン閲覧公開範囲: インターネット公開
• 関連情報（URI）: https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.00575
• 参照: Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives; https://cir.nii.ac.jp/crid/1360584340725269376
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org

• 要約等: <jats:sec><jats:title>PURPOSE</jats:title><jats:p> To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth fact...